Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment

Gynecologic Oncology

Volumn 119, Issue 3, 2010, Pages 451-456

  Blank, Stephanie V ^a   Christos, Paul ^b   Curtin, John P ^a   Goldman, Noah ^a   Runowicz, Carolyn D ^c   Sparano, Joseph A ^d   Liebes, Leonard ^a   Chen, Helen X ^e   Muggia, Franco M ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Carboplatin; Erlotinib; Ovarian cancer; Paclitaxel; Reassessment surgery

Indexed keywords

CARBOPLATIN; ERLOTINIB; PACLITAXEL;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONSTIPATION; CYTOREDUCTIVE SURGERY; DIARRHEA; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENE AMPLIFICATION; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOKALEMIA; INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SECOND LOOK SURGERY; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENES, ERBB-1; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; YOUNG ADULT;

EID: 78149360639     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.08.008     Document Type: Article

References (29)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
3. S.L. Wethington, T.J. Herzog, and V.E. Seshan Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer Cancer 113 2008 3298 3306
4. L. Huang, K.A. Cronin, K.A. Johnson, A.B. Mariotto, and E.J. Feuer Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer? Cancer 112 2008 2289 2300
5. M.A. Bookman, M.F. Brady, and W.P. McGuire Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup J Clin Oncol 27 2009 1419 1425
6. S. Stadlmann, U. Gueth, and U. Reiser Epithelial growth factor receptor status in primary and recurrent ovarian cancer Mod Pathol 19 2006 607 610
7. A. Psyrri, M. Kassar, and Z. Yu Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer Clin Cancer Res 11 2005 8637 8643
8. S.K. Blick, and L.J. Scott Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer Drugs 67 2007 2585 2607
9. S.M. Hoy, and A.J. Wagstaff Panitumumab: in the treatment of metastatic colorectal cancer Drugs 66 2006 2005 2014 discussion 2015-6.
10. P.A. Tang, M.S. Tsao, and M.J. Moore A review of erlotinib and its clinical use Expert Opin Pharmacother 7 2006 177 193
11. J.E. Frampton, and S.E. Easthope Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer Drugs 64 2004 2475 2492
12. Q. Dai, Y.H. Ling, and M. Lia Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines Clin Cancer Res 11 2005 1572 1578
13. L. Qiu, W. Di, and Q. Jiang Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death Int J Oncol 27 2005 1441 1448
14. A.N. Fader, and P.G. Rose Role of surgery in ovarian carcinoma J Clin Oncol 25 2007 2873 2883
15. R.S. Go, and A.A. Adjei Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin J Clin Oncol 17 1999 409 422
16. E. Caretti, K. Devarajan, and R. Coudry Comparison of RNA amplification methods and chip platforms for microarray analysis of samples processed by laser capture microdissection J Cell Biochem 103 2008 556 563
17. W.P. McGuire, W.J. Hoskins, and M.F. Brady Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6
18. F.M. Muggia, P.S. Braly, and M.F. Brady Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study J Clin Oncol 18 2000 106 115
19. H. Lassus, H. Sihto, and A. Leminen Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma J Mol Med 84 2006 671 681
20. R.J. Schilder, H.B. Pathak, and A.E. Lokshin Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash Gynecol Oncol 113 2009 21 27
21. R.J. Schilder, M.W. Sill, and X. Chen Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study Clin Cancer Res 11 2005 5539 5548
22. A.N. Gordon, N. Finkler, and R.P. Edwards Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study Int J Gynecol Cancer 15 2005 785 792
23. D. Cunningham, Y. Humblet, and S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
24. R. Perez-Soler, A. Chachoua, and L.A. Hammond Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 2004 3238 3247
25. R. Perez-Soler, and L. Saltz Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23 2005 5235 5246
26. F.A. Shepherd, J. Rodrigues Pereira, and T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
27. D.R. Spigel, M. Lin, V. O'Neill, and J.D. Hainsworth Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer Cancer 112 2008 2749 2755
28. R.S. Herbst, D. Prager, and R. Hermann TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 2005 5892 5899
29. U. Gatzemeier, A. Pluzanska, and A. Szczesna Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 25 2007 1545 1552